Neurotoxic effects associated with antibiotic use: Management considerations

British Journal of Clinical Pharmacology

Volumn 72, Issue 3, 2011, Pages 381-393

  Grill, Marie F ^a   Maganti, Rama K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Barrow Clinic   (United States)

Author keywords

Antibiotics; Encephalopathy; Neurotoxicity; Seizures; Toxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; GEMIFLOXACIN; GENTAMICIN; GYRASE INHIBITOR; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; NITROFURANTOIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

AGING; AGITATION; ANTIBIOTIC THERAPY; APNEA; ARACHNOIDITIS; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ATAXIA; AUDITORY HALLUCINATION; AUTONOMIC NEUROPATHY; BELL PALSY; BRAIN DISEASE; BRAIN VENTRICULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHOREA; CONFUSION; CRANIAL NEUROPATHY; CRITICAL ILLNESS; DELIRIUM; DELUSION; DIPLOPIA; DISEASE PREDISPOSITION; DISTAL PARESTHESIA; DIZZINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG WITHDRAWAL; DYSARTHRIA; ECHOLALIA; ELECTROENCEPHALOGRAM; EOSINOPHILIA; EPILEPTIC STATE; EPILEPTOGENESIS; EXTRAPYRAMIDAL SYMPTOM; FLAPPING TREMOR; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERSALIVATION; INSOMNIA; INTRACRANIAL HYPERTENSION; INTRACRANIAL HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB DYSESTHESIA; MYALGIA; MYASTHENIA LIKE SYNDROME; MYOCLONUS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; NYSTAGMUS; OPTIC NERVE DISEASE; OPTIC NEURITIS; OROFACIAL DYSKINESIA; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PLEOCYTOSIS; POLYNEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; PTOSIS; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; RESTLESSNESS; RISK FACTOR; SEIZURE; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; SWEATING; TARDIVE DYSKINESIA; TREMOR; VERTIGO; VISUAL DISORDER; VISUAL HALLUCINATION;

ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM; ELECTROENCEPHALOGRAPHY; HUMANS; NEUROTOXICITY SYNDROMES; RISK FACTORS;

EID: 79961149379     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03991.x     Document Type: Article

References (130)

1. Snavely S, Hodges G. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104.
2. Chow KM, Hui KC, Szetp CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24: 649-53.
3. Chow K, Szeto CC, Hui AC, Li PK. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrobial Agents 2004; 23: 213-7.
4. Bischoff A, Meier C, Roth F. Gentamicin neurotoxicity (polyneuropathy - encephalopathy). Schweiz Med Wochenschr 1977; 107: 3-8.
5. Watanabe I, Hodges GR, Dworzack DL, Kepes JJ, Duensing GF. Neurotoxicity of intrathecal gentamicin: a case report and experimental study. Ann Neurol 1978; 4: 564-72.
6. Hashimoto Y, Shima T, Matsukawa S, Satou M. A possible hazard of prolonged neuromuscular blockade by amikacin. Anesthesiology 1978; 49: 219-20.
7. Boliston TA, Ashman R. Tobramycin and neuromuscular blockade. Anaesthesia 1978; 33: 552.
8. Lee C, de Silva AJ. Interaction of neuromuscular blocking effects of neomycin and polymyxin B. Anesthesiology 1979; 50: 218-20.
9. Paradelis AG, Triantaphyllidis C, Giala MM. Neuromuscular blocking activity of aminoglycoside antibiotics. Methods Find Exp Clin Pharmacol 1980; 2: 45-51.
10. Segal JA, Harris BD, Kustova Y, Basile A, Skolnick P. Aminoglycoside neurotoxicity involves NMDA receptor activation. Brain Res 1999; 815: 270-7.
11. Darlington CL, Smith PF. Vestibulotoxicity following aminoglycoside antibiotics and its prevention. Curr Opin Investig Drugs 2003; 4: 841-7.
12. Fiekers JF. Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular transmission. II. Postsynaptic considerations. J Pharmacol Exp Ther 1983; 225: 496-502.
13. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestsations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42: 1843-50.
14. Roncon-Albuquerque R Jr, Pires I, Martins R, Real R, Sousa G, von Hafe P. Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection. Neth J Med 2009; 67: 72-5.
15. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911-8.
16. Dakdouki GK, Al-Awar GN. Cefepime-induced encephalopathy. Int J Infect Dis 2004; 8: 59-61.
17. Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008; 23: 966-70.
18. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and cetafzidime. Pharmacotherapy 2003; 23: 369-73.
19. Barbey F, Bugnon D, Wauters JP. Severe neurotoxicity of cefepime in uremic patients. Ann Intern Med 2001; 135: 1011.
20. Bragatti JA, Rossato R, Ziomkowski S, Kleimann FA. Cefepime-induced encephalopathy: clinical and electroencephalographic features in seven patients. Arq Neuropsiquiatr 2005; 63: 87-92.
21. Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002; 28: 214-7.
22. De Silva DA, Pan AB, Lim SH. Cefepime-induced encephalopathy with triphasic waves in three Asian patients. Ann Acad Med Singapore 2007; 36: 450-1.
23. Capparelli FJ, Diaz MF, Hiavnika A, Wainsztein NA, Leiguarda R, Del Castillo ME. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 2005; 65: 1840.
24. Herishanu YO, Zlotnik M, Mostoslavsky M, Podgaietski M, Frisher S, Wirguin I. Cefuroxime-induced encephalopathy. Neurology 1998; 50: 1873-5.
25. Ortiz A. Cefazolin-induced neurotoxicity. Clin Infect Dis 1992; 14: 624.
26. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006; 26: 1169-74.
27. Ferrara N, Abete P, Giordano M, Ferrara P, Carnovale V, Leosco D, Beneduce F, Ciarambino T, Varricchio M, Rengo F. Neurotoxicity induced by Cefepime in a very old hemodialysis patient. Clin Nephrol 2003; 59: 388-90.
28. Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant 1999; 14: 2265-6.
29. Paul M, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 58: 479-80.
30. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990; 48: 268-76.
31. Abanades S, Nolla J, Rodriguez-Campello A, Pedro C, Valls A, Farre M. Reversible coma secondary to cefepime neurotoxicity. Ann Pharmacother 2004; 38: 606-8.
32. Eggers V, Fugener K, Hein OV, Rommelspacher H, Heyes MP, Kox WJ, Spies CD. Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy. Intensive Care Med 2004; 30: 1544-51.
33. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24: 649-53.
34. Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, Mochizukie Y, Terai T, Matsuoka N. Evidence for the involvement of GABA(A) receptor blockage in convulsions induced by cephalosporins. Neuropharmacology 2003; 45: 304-14.
35. Saito T, Nakamura M, Watari M, Isse K. Tardive seizures and antibiotics: case reports and review of the literature. J ECT 2008; 24: 275-6.
36. Lin CS, Cheng CJ, Chou CH, Lin SH. Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci 2007; 333: 181-4.
37. Huang WT, Hsu YJ, Chu PL, Lin SH. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009; 37: 374-6.
38. Shaffer CL, Davey AM, Ransom JL, Brown YL, Gal P. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. Ann Pharmacother 1998; 32: 482-4.
39. Kolb R, Gogolak G, Huck S, Jaschek I, Stumpf C. Neurotoxicity and CSF level of three penicillins. Arch Int Pharmacodyn Ther 1976; 222: 149-56.
40. Contreras S, Kramer MV, Pesce ME. Electroencephalographic effects of flucloxacillin in rats. Pharmacol Toxicol 1993; 72: 205-7.
41. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991; 27: 405-25.
42. Gutnick MJ, Prince DA. Penicillinase and the convulsant action of penicillin. Neurology 1971; 21: 759-64.
43. Shiraishi H, Ito M, Go T, Mikawa H. High doses of penicillin decreases [3H] flunitrazepam binding sites in rat neuron primary culture. Brain Dev 1993; 15: 356-61.
44. Campise M. Neurological complications during imipenem/cilastatin therapy in uremic patients. Nephrol Dial Transplant 1998; 13: 1895-6.
45. Rivera M, Cresp M, Teruel JL, Marcen R, Ortuno J. Neurotoxicity due to imipenem/cilastatin in patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1998; 14: 258-9.
46. Lamoth F, Erard V, Asner S, Buclin T, Calandra T, Marchetti O. High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. Int J Antimicrobial Agents 2009; 34: 368-8.
47. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005; 39: 352-6.
48. Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122-5.
49. Ortho-McNeil Pharmaceutical. Ortho-McNeil Pharmaceutical: Doribax (Doripenem) Package Insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, 2007.
50. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006; 222: 114-24.
51. Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am 2009; 23: 983-96; ix.
52. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. Seizures in the critically ill: the role of imipenem. Epilepsia 2001; 42: 1590-3.
53. Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot 1995; 48: 408-16.
54. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104.
55. Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J 1991; 87: 869-74.
56. Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudo tumor cerebri induced by tetracycline therapy. Acta Neurol Scand 2004; 110: 408-11.
57. Saidinejad M, Ewald MB, Shannon MW. Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration. Pediatrics 2005; 115: e739-41.
58. Cooper GS, Blades EW, Remler BF, Salata RA, Bennert KW, Jacobs GH. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology 1994; 106: 782-6.
59. Patey O, Lacheheb A, Dellion S, Zanditenas D, Jungfer-Bouvier F, Lafaix C. A rare case of cotrimoxazole-induced eosinophilic aseptic meningitis in an HIV-infected patient. Scand J Infect Dis 1998; 30: 530-1.
60. Patterson RG, Couchenour RL. Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patient. Pharmacotherapy 1999; 19: 1456-8.
61. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolides in pediatric patients. Drug Saf 1999; 20: 25-41.
62. Isaacson SH, Carr J, Rowan AJ. Ciprofloxacin induced complex partial status epilepticus manifesting as an acute confusional state. Neurology 1993; 43: 1619-21.
63. Rfidah EI, Findlay CA, Beattie TJ. Reversible encephalopathy after intravenous ciprofloxacin therapy. Pediatr Nephrol 1995; 9: 250-1.
64. Kiangkitiwan B, Doppalapudi A, Fonder M, Solberg K, Bohner B. Levofloxacin-induced delirium with psychotic features. Gen Hosp Psychiatry 2008; 30: 381-3.
65. Fernandez-Torre JL. Levofloxacin-induced delirium: diagnostic considerations (letter). Clin Neurol Neurosurg 2006; 108: 614-8.
66. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352-64.
67. Schwartz MT, Calvert JF. Potential neurologic toxicity related to ciprofloxacin. Drug Intell Clin Pharm 1990; 24: 138-40.
68. Fennig S, Mauas L. Ofloxacin-induced delirium (letter). J Clin Psychiatry 1992; 53: 137-8.
69. Hakko E, Mete B, Ozaras R, Tabak F, Ozturk R, Mert A. Levofloxacin-induced delirium. Clin Neurol Neurosurg 2005; 107: 158-9.
70. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194-8.
71. Blomer R, Bruch K, Krauss H, Wacheck W. Safety of ofloxacin - adverse drug reactions reported during phase-II studies in Europe and Japan. Infection 1986; 14: S332-S334.
72. Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987; 34: S144-S149.
73. De Bleecker JL, Vervaet VL, De Sarro A. Reversible orofacial dyskinesia after ofloxacin treatment. Mov Disord 2004; 19: 731-2.
74. Pastor P, Motinho E, Elizalde I, Cirera I, Tolosa E. Reversible oro-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride. J Neurol 1996; 243: 616-7.
75. Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother 1996; 30: 138-41.
76. MacLeod W. Case report: severe neurologic reaction to ciprofloxacin. Can Fam Physician 2001; 47: 553-55.
77. Lowe MN, Lamb HM. Gemifloxacin. Drugs 2000; 59: 1137-47.
78. Ball P, Mandell L, Patou G, Danker W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrobial Agents 2004; 23: 421-9.
79. Akahane K, Tsutomi Y, Kimura Y, Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy 1994; 40: 412-7.
80. Zhang LR, Wang YM, Chen BY, Cheng NN. Neurotoxicity and toxicokinetics of norfloxacin in conscious rats. Acta Pharmacol Sin 2003; 24: 605-9.
81. Lee CH, Cheung RT, Chan TM. Ciprofloxacin-induced oral-facial dyskinesia in a patient with normal liver and renal function. Hosp Med 2000; 61: 142-3.
82. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704-8.
83. Fletcher J, Aykroyd LE, Feucht EC, Curtis JM. Early onset probable linezolid-induced encephalopathy. J Neurol 2010; 257: 433-5.
84. Thai XC, Bruno-Murtha LA. Bell's palsy associated with linezolid therapy: case report and review of neuropathic adverse events. Pharmacotherapy 2006; 26: 1183-9.
85. Ferry T, Ponceau B, Simon M, Issartel B, Petiot P, Boibieux A, Biron F, Chidiac C, Peyramond D. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005; 33: 151-4.
86. th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002; 34-5.
87. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
88. Cox AD, Harrison LH. Intravenous sodium colistimethate therapy of urinary tract infections: pharmacological and bacteriological studies. Antimicrob Agents Chemother 1970; 10: 296-302.
89. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med 1972; 266: 759-62.
90. Geelhoed GW, Ketcham AS. Pseudomonas meningitis complicating radical resection for radiorecurrent cancer of the paranasal sinuses: report of two patients successfully treated with intrathecal polymyxin. J Surg Oncol 1973; 5: 365-74.
91. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58: 1078-81.
92. Hoeprich PD. The polymyxins. Med Clin North Am 1970; 54: 1257-65.
93. Berlana D, J, Li J, Rayner CR, Nation RL. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005; 62: 39-47.
94. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
95. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistent Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: e154-60.
96. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54: 566-9.
97. Weinstein L, Doan TL, Smith MA. Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports. Am J Health Sys Pharma 2009; 66: 345-7.
98. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-62.
99. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
100. Fekety FR Jr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962; 57: 214-29.
101. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
102. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21.
103. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973; 56: 31-5.
104. McQuillen MP, Cantor HA, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol 1968; 18: 402-15.
105. Kubikowski P, Szreniawski Z. The mechanism of the neuromuscular blockade by antibiotics. Arch Int Pharmacodyn Ther 1963; 146: 549-60.
106. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
107. Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, Milne RW, Couthard K, Turnidge JD. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 2008; 52: 1159-61.
108. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971; 124: 394-400.
109. Perkins RL. Apnea with intramuscular colistin therapy. JAMA 1964; 190: 421-4.
110. Decker DA, Fincham RW. Respiratory arrest in myasthenia gravis with colistimethate therapy. Arch Neurol 1971; 25: 141-4.
111. Patel K, Green-Hopkins I, Lu S, Tunkel AR. Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. Int J Infect Dis 2008; 12: e111-4.
112. Ahmed A, Loes DJ, Bressler EL. Reversible resonance imaging in metronidazole-induced encephalopathy. Neurology 1995; 45: 588-9.
113. Tan CH, Chen YF, Chen CC, Chao CC, Liou HH, Hsieh ST. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry 2010; 82: 462-5. [Epub ahead of print].
114. Sarma GR, Kamath V. Acute painful neuropathy due to metronidazole. Neurol India 2005; 53: 372-3.
115. McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Exp Ophthalmol 2007; 35: 585-6.
116. Hobson-Webb LD, Roach ES, Donofrio PD. Metronidazole: newly recognized causes of autonomic neuropathy. J Child Neurol 2006; 21: 429-31.
117. Frytak S, Moertel CH, Childs DS, Albers JW. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978; 88: 361-2.
118. Malone RP, Harvey JA. Abnormal movements with the addition of clindamycin to risperidone in a girl with autism. J Child Adolesc Psychopharmacol 2008; 18: 221-2.
119. Nava-Ocampo AA, Mojica-Madera JA, Villanueva-Garcia D, Caltenco-Serrano R. Antimicrobial therapy and local toxicity of intraventricular administration of vancomycin in a neonate with ventriculitis. Ther Drug Monit 2006; 28: 474-6.
120. Bafeltowska JJ, Buszman E, Mandat KM, Bafeltowska JJ, Buszman E, Mandat KM, Hawranek JK. Therapeutic vancomycin monitoring in children with hydrocephalus during treatment of shunt infections. Surg Neurol 2004; 62: 142-50.
121. Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004; 172: 448-53.
122. Toole JF, Parrish ML. Nitrofurantoin polyneuropathy. Neurology 1973; 23: 554.
123. Corragio MJ, Gross TP, Roscelli JD. Nitrofurantoin toxicity in children. Pediatr Infect Dis J 1989; 8: 163.
124. D'Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm 1985; 19: 540.
125. Sharma DB, James A. Letter: Benign intracranial hypertension associated with nitrofurantoin therapy. Br Med J 1974; 4: 771.
126. Venegas-Francke P, Fruns-Quintana M, Oporto-Caroca M. Bilateral optic neuritis caused by chloramphenicol. Rev Neurol 2000; 31: 699-700.
127. Ramilo O, Kinane BT, McCracken GH Jr. Chloramphenicol neurotoxicity. Pediatr Infect Dis J 1988; 7: 358-9.
128. Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S. Cefepime neurotoxicity with overdosage recovered with high-volume hemofiltration. J Antimicrob Chemother 2008; 62: 849-50.
129. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45: 3148-55.
130. Mazzeo F, Capuano A, Avolio A, Filippelli A, Rossi F. Hospital-based intensive monitoring of antibiotic-induced adverse events. Pharmacol Res 2005; 51: 269-74.